Abstract Leukemia cutis is the term used for cutaneous manifestations of leukemia, which can have varied clinical presentations. A skin biopsy can help in diagnosing such condition and differentiating it from other skin diseases. We present a case where a 45 years old man presented with diffuse papulovesicular skin lesions mimicking dessiminated herpes. Further workup revealed patient having acute myeloid leukemia (AML-M2) and skin biopsy showed infiltration by myeloblasts. With chemotherapy patient went into remission and skin lesions healed.
A 45 years old male presented with papulovesicular skin eruptions (Figs. 1, 2) and high grade fever for 10 days. He was referred to our institute with suspected dessiminated herpes. He was evaluated and found to have high total leukocyte count of 46 9 10 9 /l (normal range 4-11 9 10 9 /l) with 80% blasts on differential count on peripheral smear. His hemoglobin was 9.2 g/dl and platelet counts were 70 9 10 9 (normal range 150-450 9 10 9 /l). The detailed bone marrow analysis including morphology, cytochemistry, cytogenetics and immunophenotyping revealed acute myeloid leukemia with maturation, not otherwise categorised (AML-M2). The blasts were positive for myeloperoxidase (MPO). Skin biopsy showed bulae with spongiosis with presence of neutrophils and myeloblasts in subepidermal region which were positive for MPO on immunohistochemistry ( Fig. 3 ). There were no fungal elements or viral inclusion bodies. Polymerase chain reaction for herpes simplex virus (HSV-PCR) was negative.
The patient received the standard 3 ? 7 induction chemotherapy for AML including cytarabine (100 mg/m 2 /day; 7 day infusion) and daunorubicin (45 mg/m 2 /day on day 1 to 3). Subsequently, there was progressive reduction in the appearance of new lesions and healing of old lesions. After day 16 of induction chemotherapy, no new lesions appeared. Day 28 bone marrow examination revealed it to be in remission. Hyperpigmented scarred lesions could be visualised on day 28 post-chemotherapy (Fig. 4) . infiltration, cytological features and the immunophenotyping or cytochemistry of tumor cells [2, 3] . Correlation with clinical data and bone marrow and peripheral blood findings is often helpful to confirm the diagnosis. Biopsy may reveal prominent diffuse infiltrate involving the deep dermal surface but preservation of the superficial dermis. Skin involvement has been emphasized as a feature of monocytic leukemias, however it occurs equally frequently in myeloblastic as in monocytic leukemias [4, 5] . Like other forms of extramedullary disease, leukemia cutis usually portends a poor prognosis in patients with AML. The prognosis for leukemia cutis is related directly to the prognosis for the systemic disease. Therapy is usually directed at the underlying leukemia [6] . Treatment of acute myeloid leukemia involves induction chemotherapy followed by consolidation with multiple courses of high dose cytarabine or stem cell transplantation. Leukemia cutis present at the time of diagnosis of AML in the bone marrow may be successfully treated with chemotherapy alone, and resistant or recurrent skin disease may then be treated with electron-beam therapy followed by reinduction and/or consolidation chemotherapy. Our patient was treated with induction chemotherapy resulting in disease remission with nearly complete resolution of skin lesions. At present patient is in complete remission after 6 months of follow up. 
